Nasdaq tonight, page-3

BY RAYMON PICKLE • MAY 26 2015 Wall Street Observer (Published just some time go NY time)
Biotech Stocks Attracting Some Extra Attention Prima Biomed (PBMD)
BY RAYMON PICKLE • MAY 26 2015 Wall Street Observer

Prima Biomed Ltd. (NASDAQBMD) added +3.28% to complete last trading session at $3.15. The company, on May 19, 2015, announced that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial has shown a trend for a clinically meaningful improvement in Overall Survival (“OS”) over standard of care (“SOC”) in second remission patients. In the group of second remission patients (n=20), the median for standard of care (“SOC”) patients was 25.53 months, which is consistent with current literature. By comparison, for patients treated with CVac a median has still not yet been reached after 42 months with study completion and closure. This suggests a striking improvement with a hazard ratio1 = 0.17 (95%CI: 0.02, 1.44; p=0.07). This implies at least a 16 months median survival advantage for second remission patients when treated with CVac.